CTIS2023-505375-75-00招募中1 期
SGLT2 inhibitor TrEatment iN patients awaiting cOronary arTery bYpass surgery to reduce Post-opErative atrial fibrillation and kidney injury (STENOTYPE trial). - STENOTYPE-2023
Region Oerebro Laen0 个研究点目标入组 800 人开始时间: 2023年9月28日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 800
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •1)The subject has given their written consent to participate in the trial., 2)Subject is =18 years at the time of written consent., 3)Chronic coronary syndrome documented by coronary angiography, scheduled for CABG surgery with extra corporeal circulation. OR Patients with chronic coronary syndrome scheduled for CABG surgery with extra corporeal circulation and aortic valve replacement with extra corporeal circulation. AND/OR Patients with chronic coronary syndrome scheduled for CABG surgery with extra corporeal circulation and mitral valve replacement or repair with extra corporeal circulation. AND/OR Patients with chronic coronary syndrome scheduled for CABG surgery with extra corporeal circulation and aortic root surgery with extra corporeal circulation.
排除标准
- •1)Treatment with an SGLT2 inhibitor within 8 weeks prior to enrolment or planned treatment., 10)Any condition such as, but not limited to, malignancy, with a life expectancy of <2 years based on the investigator’s clinical judgement., 11)Hepatic impairment (aspartate transaminase or alanine transaminase >3 × the upper limit of normal, or total bilirubin >2 × upper limit of normal at the time of enrolment)., 12)Severe (estimated GFR < 25 mL/min/1.73 m2), unstable, or rapidly progressing renal disease at the time of enrolment., 13)CABG surgery planned within one week, 14)Emergency surgery with hemodynamic instability., 15)Previous history of AF., 16)Women of childbearing potential (i.e., those who are fertile, following menarche and until becoming post-menopausal, unless permanently sterile*) a.Who are not willing to use a highly effective method of contraception** judged by the investigator, from the time of signing the informed consent throughout the trial and 4 weeks thereafter, OR b. Who have a positive pregnancy test at enrolment or randomization, OR c. Who are breast-feeding., 17)Participation or recent participation in a clinical trial with an IMP within 30 days before randomization., 18)Previous randomization in the STENOTYPE trial., 19)Previous (within 30 days) or concomitant participation in another clinical trial with an investigational product. Registries and observational studies are allowed., 2)Intolerance, hypersensitivity, or other contraindications of dapagliflozin., 20)Mental inability, reluctance, or language difficulties of the subject, in the opinion of the investigator, that result in difficulty in understanding the meaning of participation in the trial., 3)Type 1 diabetes mellitus., 4)Symptomatic hypotension or systolic blood pressure <95 mmHg at two out of three measurements at enrolment., 5)Current acute decompensated HF or hospitalization due to decompensated HF <4 weeks prior to enrolment., 6)Heart failure due to restrictive cardiomyopathy, active myocarditis, constrictive pericarditis, or hypertrophic cardiomyopathy., 7)Implantation or intent to implant a cardiac resynchronization device within 12 weeks prior to enrolment., 8)Stroke or transient ischemic attack within 12 weeks prior to enrolment., 9)Symptomatic bradycardia or second or third-degree atrioventricular block without pacemaker treatment.
研究者
相似试验
招募中
4 期
Effects of SGLT-2 inhibitors for the patients with non-alcoholic fatty liver disease (NAFLD) complicated with type 2 diabetes mellitus.on-alcoholic fatty liver disease (NAFLD) complicated with type 2 diabetes mellitus.JPRN-UMIN000018913Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine50
招募中
不适用
Efficacy and Safety of SGLT2 inhibitors in patients with type 1 diabete.type 1 diabetesJPRN-UMIN000044317Hokkaido University Hospital200
已完成
Unknown
Prospective observational study of tofogliflozin in patients with type 2 diabetesType 2 DiabetesJPRN-jRCT1090220212agoya Medical Association600
进行中（未招募）
不适用
Combination of SGLT2 inhibitor and Intensive Exercise in Diabetes.JPRN-jRCTs071180050Yoshihiro Ogawa146
已完成
不适用
The efficacy and safety of SGLT2 inhibitor for non alcholic fatty liver disease in Japanese patients with type 2 diabetesJPRN-UMIN000016306Tokyo Medical and Dental University50